Cliniphar (TSE:432A) Total Operating Expense: 円509 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:432A Cliniphar Ltd TSE:432A
20 GF Score
Price 円1,450.00
! 3 Warning Signs
View Full Analysis

What is Cliniphar Total Operating Expense?

Cliniphar TSE:432A 20 Total Operating Expense is 円509 Mil as of Mar. 2026. GuruFocus rates TSE:432A with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

Cliniphar's Total Operating Expense for the six months ended in Mar. 2026 was 円509 Mil. Cliniphar's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was 円509 Mil.

Cliniphar Total Operating Expense Related Terms

Cliniphar Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Cliniphar's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cliniphar Total Operating Expense Chart

Cliniphar Annual Data
Trend Mar24 Mar25 Mar26
Total Operating Expense
506.98 517.04 509.19

Cliniphar Semi-Annual Data
Mar24 Mar25 Mar26
Total Operating Expense 506.98 517.04 509.19
TSE:432A
20GF Score
Cliniphar Ltd TSE:432A
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cliniphar Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was 円509 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of 円509 Mil mean?
Cliniphar (TSE:432A) has a Total Operating Expense of 円509 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Cliniphar and its competitors.
Is Cliniphar's Total Operating Expense too high?
Cliniphar's current Total Operating Expense is 円509 Mil. Overall, Cliniphar has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Cliniphar's Total Operating Expense compare to competitors?
Cliniphar's Total Operating Expense of 円509 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Healthcare Providers & Services company?
A good Total Operating Expense depends on the Healthcare Providers & Services industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Cliniphar and its competitors. Cliniphar's current Total Operating Expense is 円509 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cliniphar stock overvalued right now?
Cliniphar (TSE:432A) has a current Total Operating Expense of 円509 Mil. The current Total Operating Expense is 円509 Mil. Cliniphar's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Cliniphar (TSE:432A), the current Total Operating Expense is 円509 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cliniphar Business Description

Address 1-7-31, Otemae, 5th Floor, OMM Building, Otemae, Chuo-ku, Osaka-shi, Osaka, JPN, 540-0008
Cliniphar Ltd is engaged in Pharmaceutical Wholesale and Distribution Business for Domestic and International Markets.
20GF Score

Get the complete analysis for TSE:432A

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,450.00
Price